AzTrials
AzTrials

Ischemic StrokeMtH-DETECTNCT06585228

Detecting Cardiac Thrombi in Acute Ischemic Stroke on Cardiac CT Versus Transoesophageal Echocardiography

An observational study of Ischemic Stroke and Cardioembolic Stroke, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Rationale: Cardiac CT acquired during the acute stroke imaging protocol (acute cardiac CT) has recently been shown to have a superior diagnostic yield than transthoracic echocardiography, which is currently the most commonly used method to screen for structural sources of cardioembolism in patients with acute ischemic… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Cardiac Computed Tomography, Transesophageal echocardiography and Repeated Cardiac Computed Tomography
How many people
39 participants
Where
1 siteNetherlands
Study dates
19 Aug 2024to 1 Oct 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients 18 years or older with acute ischemic stroke and a LA thrombus detected on cardiac CT acquired during the initial stroke imaging protocol at Amsterdam UMC, location AMC.

Who may be able to join

  • Age 18 years or older
  • Clinical diagnosis of acute ischemic stroke
  • Written informed consent from patient or representative
  • Radiological diagnosis of cardiac thrombus in the LA, including the LAA, on cardiac CT acquired during the initial stroke imaging protocol.

Who cannot join

  • Patients with a diagnosis other than acute ischemic stroke, such as: transient ischemic attack, intracerebral haemorrhage, subarachnoid haemorrhage, epilepsy, tumor.
  • Absolute contraindication for TEE:
  • Perforated viscus
  • Esophageal stricture
  • Esophageal tumor
  • Esophageal perforation, laceration
Show all 11Show fewer
  • Esophageal diverticulum
  • Active upper GI bleed
  • Absolute contraindication for repeat cardiac CT
  • Documented previous severe reaction to iodinated contrast media, including anaphylaxis, angioedema and bronchospasm.
  • Severely impaired kidney function defined as estimated glomerular filtration rate of 30 mL/min/1.73 m2.

Trial locations and contacts

1 site in 1 country.

Jonathan M Coutinho, MD, PhD contact

0205662004 ext. 0031

j.coutinho@amsterdamumc.nl

Netherlands1 site, 1 recruiting
  • Amsterdam University Medical Center (UMC)

    Amsterdam, North Holland, 1105AZ

    Shan Sui Nio, MD, 020 5664591 ext. 0031, s.nio@amsterdamumc.nl

    Recruiting

Other trials in Netherlands

About this study

Official title: Detecting Cardiac Thrombi in Acute Ischemic Stroke on Cardiac CT Versus Transoesophageal Echocardiography (MtH-DETECT)

Rationale:

Cardiac CT acquired during the acute stroke imaging protocol (acute cardiac CT) has recently been shown to have a superior diagnostic yield than transthoracic echocardiography, which is currently the most commonly used method to screen for structural sources of cardioembolism in patients with acute ischemic stroke. The most common finding on acute cardiac CT are cardiac thrombi located in the left atrium (LA) and specifically the left atrial appendage (LAA). The higher diagnostic yield of acute cardiac CT compared to TTE is partially explained because CT allows for better visualization of the LAA, but also because cardiac thrombi may dissolve in the first days after stroke. Whether acute cardiac CT is the optimal diagnostic modality for LA thrombi in stroke patients is unknown, since data comparing it to transoesophageal echocardiography (TEE), which is the reference standard to detect LA thrombi, are lacking. The general hypothesis of this study is that acute cardiac CT is the optimal method to detect LA thrombi in ischemic stroke patients, since TEE can miss LA thrombi that dissolve in the first days after stroke.

Read more

Objectives:

  1. Determine whether acute cardiac CT has a higher diagnostic probability of detecting LA thrombi compared to TEE or repeated cardiac CT in the subacute phase of ischemic stroke by assessing the rate at which LA thrombi dissolve in the first days after ischemic stroke occurrence.
  2. Determine the positive predictive value of acute cardiac CT compared to TEE for the detection of LA thrombi. Study design: Prospective, single-centre, observational cohort Study population: 39 patients of 18 years or older with acute ischemic stroke and a LA thrombus detected on cardiac CT acquired during the acute stroke imaging.

Main study parameters/endpoints:

  1. Rate at which LA thrombi visualized on acute cardiac CT dissolve in the first days after ischemic stroke.
  2. False-positive rate for detection of left atrial thrombi on acute cardiac CT compared to TEE. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Clinical and imaging patient data which are obtained as part of standard care will be prospectively collected after written informed consent. Patient with a LA thrombus on acute cardiac CT will undergo TEE for research purposes after obtaining written informed consent. TEE is semi-invasive and associated with a small risk of major complications (<0.2%). Patients will also be exposed to additional radiation (1.4 mSV) due to sequential cardiac CT after TEE. The Radiation Dose Committee deemed this to be an intermediate risk. In a small minority of patients (<10%), another cardiac CT will be acquired 2 minutes after this sequential cardiac CT to ensure a clear, final assessment of the presence of an atrial appendage thrombus. This will result in a total additional radiation of 3 mSV for the two additional cardiac CT's. The Radiation Dose Committee deemed this to be an intermediate risk. As part of standard care, patients will be contacted for follow-up evaluation by a trained stroke nurse at 90 days. As a result of ischemic stroke, some patients become incapacitated to an extent they are unable to give informed consent. In these cases, the legal representative will be asked for informed consent. Decreased leveI of consciousness or aphasia are typical clinical characteristics of cardioembolic stroke. Therefore, it is pivotal to also include incapacitated acute ischemic stroke patients. Excluding these patients from the study would render the study non-representative of the study's target population (acute ischemic stroke patients with cardioembolic stroke due to LA thrombus).
Being tested
Cardiac Computed Tomography, Transesophageal echocardiography, Repeated Cardiac Computed Tomography
Keywords
Cardiac CT, Transoesophageal echocardiography, Ischemic stroke
Medical subject headings
Ischemic Stroke, Embolic Stroke, Thromboembolism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cardiac Computed TomographyDiagnostic test

    Also called Cardiac CT, CCT

    Cardiac CT acquired during the acute stroke imaging protocol

  • Transesophageal echocardiographyDiagnostic test

    Also called TEE

    Ultrasound through the oesophagus to assess cardiac structures.

  • Repeated Cardiac Computed TomographyDiagnostic test

    Also called Cardiac CT

    A second cardiac CT performed after the TEE.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of patients with a left atrial thrombus

    The proportion of patients with a LA thrombus detected on acute cardiac CT that dissolves in the first days after stroke, defined as thrombi that are seen on initial cardiac CT but are no longer visible on TEE and repeated cardiac CT.

    Measured: The assessment of a left atrial thrombus is performed when the patient arrives at the Emergency Department and undergoes the acute stroke imaging protocol including a cardiac CT.

  2. Positive predictive value of acute cardiac CT compared to TEE.

    Positive predictive value of acute cardiac CT compared to TEE.

    Measured: The assessment of a left atrial thrombus is performed when the patient arrives at the Emergency Department and undergoes the acute stroke imaging protocol including a cardiac CT. The TEE is performed <7 days after the cardiac CT.

Secondary outcomes (2)
  1. Other pre-defined high-risk and non-high-risk sources of embolism on cardiac CT and TEE

    Other high-risk and non-high-risk sources that have been detected on cardiac CT and TEE.

    Measured: Cardiac CT is performed and assessed when the patients arrives at the Emergency Department. The TEE is performed <7 days after the cardiac CT.

  2. Clinical impact of cardiac thrombi

    The clinical impact of detecting cardiac thrombi and other sources of embolism on acute cardiac CT and TEE, including any impact on stroke etiology according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria

    Measured: The clinical data of patients with a thrombi is collected on arrival at the Emergency Department and follow-up is performed at 90 days and 2 years to assess functional outcome, recurrent stroke and cardiovascular events

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Sep 2024
  2. Study start19 Aug 2024
  3. Primary completion1 Jul 2026 (estimated)
  4. Study completion1 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
39 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06585228
Sponsor's protocol ID
NL84141.018.23
Acronym
MtH-DETECT
Status last verified
Sep 2024
First submitted
3 Sep 2024
Last updated
3 Feb 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Ischemic Stroke and Cardioembolic Stroke, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Shan Sui Nio, MD (020 5664591 ext. 0031, s.nio@amsterdamumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of patients with a left atrial thrombus (time frame: The assessment of a left atrial thrombus is performed when the patient arrives at the Emergency Department and undergoes the acute stroke imaging protocol including a cardiac CT.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in